Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
Patent 6287600 Issued on September 11, 2001. Estimated Expiration Date: 
March 20, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 20, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3781429 3927213 3928588 Stabilized E-series prostaglandins Stabilization of 16-oxygenated prostanoic acid derivatives Stabilized pharmaceutical admixture composition Pharmaceutical tablet composition Pharmaceutical composition Patent #: 5698225 InventorsApplicationNo. 528550 filed on 03/20/2000US Classes:424/472, Layered unitary dosage forms424/458, Containing discrete coated particles pellets, granules, or beads424/468, Sustained or differential release type424/490, Coated (e.g., microcapsules)514/772.3, Solid synthetic organic polymer514/781, Cellulose or derivative514/951, POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE514/970CONTAINING DESIGNATED INGREDIENT TO STABILIZE AN ACTIVE INGREDIENTExaminersPrimary: Spear, James M.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/16A61K 009/22 A61K 009/24 A61K 009/52 A61K 009/54 AbstractA pharmaceutical composition is provided for the oral administration of an NSAlD and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.Other References
Field of SearchCapsules (e.g., of gelatin, of chocolate, etc.)With claimed designated perfecting feature in contents (e.g., excipient, lubricant, etc.) Tablets, lozenges, or pills With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.) Layered unitary dosage forms Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Sustained or differential release Containing discrete coated particles pellets, granules, or beads Sustained or differential release type Coated (e.g., microcapsules) | |
